These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 574959

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The role of some prostaglandins in the interaction of fibrinogen degradation products (FDP) with central dopamine receptors of rats.
    Buczko W, Wiśniewski K.
    Pol J Pharmacol Pharm; 1979; 31(5):473-80. PubMed ID: 575732
    [Abstract] [Full Text] [Related]

  • 3. Action of fibrinopeptides A and B on the central dopaminergic system of rats pretreated with indomethacin.
    Swiderska D, Buczko W, Wiśniewski K.
    Pol J Pharmacol Pharm; 1986; 38(1):21-8. PubMed ID: 3763484
    [Abstract] [Full Text] [Related]

  • 4. Participation of prostaglandins E2 and F2 alpha in the action of fibrinopeptides A and B on the central dopaminergic system.
    Swiderska D, Buczko W, Wiśniewski K.
    Pol J Pharmacol Pharm; 1986; 38(1):29-39. PubMed ID: 3463941
    [Abstract] [Full Text] [Related]

  • 5. Influence of fibrinogen degradation products on the action of amphetamine in the central nervous system.
    Zwoliński J, Buczko W.
    Pol J Pharmacol Pharm; 1977; 29(3):313-9. PubMed ID: 560684
    [Abstract] [Full Text] [Related]

  • 6. Studies on the participation of the dopaminergic system in the central effects of chelidonine.
    Kleinrok Z, Szponar J, Matuszek B, Jagiełło-Wójtowicz E.
    Pol J Pharmacol Pharm; 1990; 42(5):417-24. PubMed ID: 2098751
    [Abstract] [Full Text] [Related]

  • 7. Further studies on the effect of fibrinopeptides A and B on the central nervous system.
    Bernacka I, Buczko W, Wiśniewski K.
    Pol J Pharmacol Pharm; 1981 Nov; 33(4):407-14. PubMed ID: 7329866
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interactions between agents stimulating and inhibiting the central dopamine receptors and octopamine.
    Jagiełło-Wójtowicz.
    Acta Physiol Pol; 1980 Nov; 31(2):153-8. PubMed ID: 6771963
    [Abstract] [Full Text] [Related]

  • 10. Central action of phenylethylamine in rats.
    Jagiełło-Wójtowicz E.
    Pol J Pharmacol Pharm; 1981 Nov; 33(1):59-71. PubMed ID: 7196039
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Some behavioural effects of chloroquine in rats suggesting dopaminergic activation.
    Amabeoku GJ.
    Indian J Med Res; 1994 Feb; 99():87-94. PubMed ID: 8005645
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of angiotensin on the central action of dopamine.
    Braszko J, Wiśniewski K.
    Pol J Pharmacol Pharm; 1976 Feb; 28(6):667-72. PubMed ID: 1034924
    [Abstract] [Full Text] [Related]

  • 18. The effect of baclofen and aminooxyacetic acid on the action of drugs stimulating the dopaminergic system.
    Sypniewska M.
    Pol J Pharmacol Pharm; 1978 Feb; 30(6):755-66. PubMed ID: 573471
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.